Omeprazole impairs the absorption of mycophenolate mofetil but not of enteric-coated mycophenolate sodium in healthy volunteers

Journal of Clinical Pharmacology

Volumn 52, Issue 8, 2012, Pages 1265-1272

  Kees, M G ^a   Steinke, T ^b   Moritz, S ^b   Rupprecht, K ^c   Paulus, E M ^d   Kees, F ^c   Bucher, M ^b   Faerber, L ^c,d  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b MARTIN LUTHER UNIVERSITÄT HALLE WITTENBERG   (Germany)

^c UNIVERSITY OF REGENSBURG   (Germany)

^d Novartis Pharma   (Germany)

Author keywords

bioavailability; drug drug interaction; HPLC; pharmacokinetics; proton pump inhibitor

Indexed keywords

MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OMEPRAZOLE;

ADULT; AREA UNDER THE CURVE; ARTICLE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG SOLUBILITY; DRUG TOLERABILITY; ENTERIC COATED TABLET; FEMALE; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PH; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADULT; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; DRUG INTERACTIONS; FEMALE; GLUCURONIDES; HUMANS; HYDROGEN-ION CONCENTRATION; MALE; MYCOPHENOLIC ACID; OMEPRAZOLE; TABLETS, ENTERIC-COATED; YOUNG ADULT;

EID: 84864397182     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270011412968     Document Type: Article

References (36)

1. Arns W, Breuer S, Choudhury S, et al. Enteric-coated mycophenolate sodium delivers bioequivalent MPA exposure compared with mycophenolate mofetil. Clin Transplant. 2005 ; 19: 199-206 (Pubitemid 40424890)
2. Rupprecht K, Schmidt C, Raspé A, et al. Bioavailability of mycophenolate mofetil and enteric-coated mycophenolate sodium is differentially affected by pantoprazole in healthy volunteers. J Clin Pharmacol. 2009 ; 49: 1196-1201
3. Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet. 2007 ; 46: 13-58 (Pubitemid 46091591)
4. Manitpisitkul W, McCann E, Lee S, Weir MR. Drug interactions in transplant patients: what everyone should know. Curr Opin Nephrol Hypertens. 2009 ; 18: 404-411
5. Miura M, Satoh S, Kagaya H, et al. Effect of telmisartan, valsartan, and candesartan on mycophenolate mofetil pharmacokinetics in Japanese renal transplant recipients. J Clin Pharm Ther. 2009 ; 34: 683-692
6. Kofler S, Deutsch M, Bigdeli AK, et al. Proton pump inhibitor co-medication reduces mycophenolate acid drug exposure in heart transplant recipients. J Heart Lung Transplant. 2009 ; 28: 605-611
7. Doesch AO, Mueller S, Konstandin M, et al. Proton pump inhibitor comedication reduces active drug exposure in heart transplant recipients receiving mycophenolate mofetil. Transplant Proc. 2010 ; 42: 4243-4246
8. Schaier M, Scholl C, Scharpf D, et al. Proton pump inhibitors interfere with the immunosuppressive potency of mycophenolate mofetil. Rheumatology (Oxford). 2010 ; 49: 2061-2067
9. Miura M, Satoh S, Inoue K, et al. Influence of lansoprazole and rabeprazole on mycophenolic acid pharmacokinetics one year after renal transplantation. Ther Drug Monit. 2008 ; 30: 46-51 (Pubitemid 351161098)
10. Kiberd BA, Wrobel M, Dandavino R, Keown P, Gourishankar S. The role of proton pump inhibitors on early mycophenolic acid exposure in kidney transplantation: evidence from the CLEAR study. Ther Drug Monit. 2011 ; 33: 120-123
11. Aresta A, Palmisano F, Zambonin CG, Schena P, Grandaliano G. Simultaneous determination of free mycophenolic acid and its glucuronide in serum of patients under mycophenolate mophetil therapy by ion-pair reversed-phase liquid chromatography with diode array UV detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2004 ; 810: 197-202 (Pubitemid 39243305)
12. Elbarbry FA, Shoker A. Simple high performance liquid chromatographic assay for mycophenolic acid in renal transplant patients. J Pharm Biomed Anal. 2007 ; 43: 788-792 (Pubitemid 44960587)
13. Bahrami G, Mohammadi B. An isocratic high performance liquid chromatographic method for quantification of mycophenolic acid and its glucuronide metabolite in human serum using liquid-liquid extraction: application to human pharmacokinetic studies. Clin Chim Acta. 2006 ; 370: 185-190 (Pubitemid 44080187)
14. Steinijans VW, Hartmann M, Huber R, Radtke HW. Lack of pharmacokinetic interaction as an equivalence problem. Int J Clin Pharmacol Ther. 1996 ; 34: S25-30
15. US Food and Drug Administration. Guidance for Industry: Drug Interaction Studies. Sep 2006. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm072101.pdf. Accessed Jun 17 2011.
16. United States Department of Veterans Affairs. Abbreviated drug class review: proton pump inhibitors. Aug2006. http://www.pbm.va.gov/reviews/ ppiabbreviatedreview.pdf. Accessed June 17, 2011.
17. Kirchheiner J, Glatt S, Fuhr U, et al. Relative potency of proton-pump inhibitors-comparison of effects on intragastric pH. Eur J Clin Pharmacol. 2009 ; 65: 19-31
18. Stedman CA, Barclay ML. Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors. Aliment Pharmacol Ther. 2000 ; 14: 963-978 (Pubitemid 30618157)
19. Vallve M, Vergara M, Gisbert JP, Calvet X. Single vs double dose of a proton pump inhibitor in triple therapy for Helicobacter pylori eradication: a meta-analysis. Aliment Pharmacol Ther.. 2002 ; 16: 1149-1156 (Pubitemid 34680759)
20. Kofler S, Shvets N, Bigdeli AK, et al. Proton pump inhibitors reduce mycophenolate exposure in heart transplant recipients-a prospective case-controlled study. Am J Transplant. 2009 ; 9: 1650-1656
21. Andersson T, Andrén K, Cederberg C, et al. Pharmacokinetics and bioavailability of omeprazole after single and repeated oral administration in healthy subjects. Br J Clin Pharmacol. 1990 ; 29: 557-563 (Pubitemid 20161305)
22. Andersson T, Röhss K, Bredberg E, Hassan-Alin M. Pharmacokinetics and pharmacodynamics of esomeprazole, the S-isomer of omeprazole. Aliment Pharmacol Ther. 2001 ; 15: 1563-1569 (Pubitemid 32912398)
23. Shi S, Klotz U. Proton pump inhibitors: an update of their clinical use and pharmacokinetics. Eur J Clin Pharmacol. 2008 ; 64: 935-951
24. Kuypers DRJ, Meur YL, Cantarovich M, et al. Consensus report on therapeutic drug monitoring of mycophenolic acid in solid organ transplantation. Clin J Am Soc Nephrol. 2010 ; 5: 341-358
25. Lidgate D, Brandl M, Holper M, Abubakari A, Wu X. Influence of ferrous sulfate on the solubility, partition coefficient, and stability of mycophenolic acid and the ester mycophenolate mofetil. Drug Dev Ind Pharm. 2002 ; 28: 1275-1283 (Pubitemid 35416655)
26. Saathoff N, Lode H, Neider K, et al. Pharmacokinetics of cefpodoxime proxetil and interactions with an antacid and an H2 receptor antagonist. Antimicrob Agents Chemother. 1992 ; 36: 796-800
27. Barraclough KA, Staatz CE, Isbel NM, Johnson DW. Therapeutic monitoring of mycophenolate in transplantation: is it justified?. Curr Drug Metab. 2009 ; 10: 179-187
28. Cantarovich M, Brown NW, Ensom MHH, et al. Mycophenolate monitoring in liver, thoracic, pancreas, and small bowel transplantation: a consensus report. Transplant Rev (Orlando). 2011 ; 25: 65-77
29. Barraclough KA, Isbel NM, Franklin ME, et al. Evaluation of limited sampling strategies for mycophenolic acid after mycophenolate mofetil intake in adult kidney transplant recipients. Ther Drug Monit. 2010 ; 32: 723-733
30. Lam S, Partovi N, Ting LSL, Ensom MHH. Corticosteroid interactions with cyclosporine, tacrolimus, mycophenolate, and sirolimus: fact or fiction?. Ann Pharmacother. 2008 ; 42: 1037-1047
31. Naesens M, Kuypers DRJ, Streit F, et al. Rifampin induces alterations in mycophenolic acid glucuronidation and elimination: implications for drug exposure in renal allograft recipients. Clin Pharmacol Ther. 2006 ; 80: 509-521 (Pubitemid 44737482)
32. Cattaneo D, Perico N, Gaspari F, Gotti E, Remuzzi G. Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation. Kidney Int. 2002 ; 62: 1060-1067 (Pubitemid 35316738)
33. Uwai Y, Motohashi H, Tsuji Y, et al. Interaction and transport characteristics of mycophenolic acid and its glucuronide via human organic anion transporters hOAT1 and hOAT3. Biochem Pharmacol. 2007 ; 74: 161-168 (Pubitemid 46802493)
34. Naderer OJ, Dupuis RE, Heinzen EL, et al. The influence of norfloxacin and metronidazole on the disposition of mycophenolate mofetil. J Clin Pharmacol. 2005 ; 45: 219-226 (Pubitemid 40490446)
35. Borrows R, Chusney G, Loucaidou M, et al. The magnitude and time course of changes in mycophenolic acid 12-hour predose levels during antibiotic therapy in mycophenolate mofetil-based renal transplantation. Ther Drug Monit. 2007 ; 29: 122-126 (Pubitemid 46279886)
36. Schmidt LE, Rasmussen A, Nørrelykke MR, Poulsen HE, Hansen BA. The effect of selective bowel decontamination on the pharmacokinetics of mycophenolate mofetil in liver transplant recipients. Liver Transpl. 2001 ; 7: 739-742 (Pubitemid 32771475)